drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy
drug_description
Autologous adoptive cell therapy comprising patient-derived tumor-reactive T cells isolated from bladder tumors, expanded ex vivo with IL-2 and anti-CD3 stimulation, and administered intravesically to treat high-grade non-muscle-invasive urothelial carcinoma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Lymphocytes, Tumor-Infiltrating
drug_category
TUMOR INFILTRATING LYMPHOCYTES
drug_class
Unedited cells
drug_delivery_route
Intravesical
drug_mechanism_of_action
Autologous tumor-infiltrating lymphocytes (TIL) are isolated from the patient’s bladder tumor, activated and expanded ex vivo with IL-2 and anti-CD3, then administered intravesically. These non-engineered T cells recognize tumor antigens via their native TCRs and mediate cytotoxicity (perforin/granzyme) and cytokine release (e.g., IFN-γ), increasing local anti-tumor immunity within the bladder.
drug_name
Tumor-Infiltrating Lymphocytes (TIL)
nct_id_drug_ref
NCT05768347